Core Viewpoint - The passing of Yin Zhenglong, the founder and chairman of Shanhe Pharmaceutical Excipients, is a significant event for the company, which has been under his leadership since its inception. The company is expected to maintain its operations and governance structure despite this loss [4][7][10]. Company Overview - Shanhe Pharmaceutical Excipients was established in April 2001 and specializes in the production, research, and sales of new pharmaceutical excipients. It has become a leading player in the domestic pharmaceutical excipients industry and was listed on the Shenzhen Stock Exchange in May 2015 [10]. - As of August 27, the company's market capitalization was approximately 3.28 billion yuan [10]. Leadership Transition - Yin Zhenglong held 63,057,454 shares, accounting for 26.90% of the total shares, making him the controlling shareholder and actual controller of the company [7]. - Following his passing, the company announced that the board of directors would not fall below the legal number of members, ensuring normal operations. Song Daocai, a current board member and general manager, will temporarily assume the role of chairman until a new chairman is elected [9][10]. Financial Performance - For the first half of 2025, Shanhe Pharmaceutical reported a revenue of 471 million yuan, a year-on-year increase of 4.65%. However, the net profit attributable to shareholders decreased by 2.61% to approximately 93 million yuan [11][12]. - The company’s cash flow from operating activities saw a significant increase of 108.53%, reaching approximately 80 million yuan [12]. - Basic earnings per share decreased by 2.44% to 0.40 yuan, while diluted earnings per share fell by 5.00% to 0.38 yuan [12]. Market Reaction - Following the news of Yin Zhenglong's passing, Shanhe Pharmaceutical's stock price dropped by 2.65%, closing at 13.96 yuan per share on August 27 [13].

安徽山河药用辅料股份有限公司（下称山河药辅或公司）27日早间公告，公司控股股东、实际控制人、董事长尹正龙逝世。 公告称，"接公司控股股东、实际控制人、董事长尹正龙先生家属的通知，尹正龙先生已于2025年8月26日下午永远离开了我们，享年60岁。" 据公司2024年年报披露的简历，尹正龙毕业于安徽中医药大学药学专业，本科学历，高级工程师，执业药师。1989年至2000年，先后任职于淮南市第五制 药厂、淮南山河药业有限公司，担任技术科长、副总经理、总工程师等职务；2001年至今，任公司董事长(其中2001年至2024年8月兼任公司总经理)；现 为安徽省政协委员、安徽省工商联副主席、淮南市人大常委、淮南市工商联副主席、中国化学制药工业协会副会长、安徽省医药行业协会副会长、中国药 用辅料产业联盟副主任、安徽省专精特新中小企业联盟副理事长；是安徽理工大学和安徽中医药大学外聘教授和工程硕士生导师。曾获安徽省五一劳动 奖、安徽省劳动模范，安徽省新兴技术产业领军人才，安徽省优秀民营企业家，安徽省30佳创新企业家，安徽省优秀中国特色社会主义建设者，安徽省非 公有制经济优秀创业者，省特支计划首批创新领军人才等荣誉称号。 企业官网 ...

每经编辑｜陈柯名 安徽山河药用辅料股份有限公司（下称山河药辅或公司）27日早间公告，公司控股股东、实际控制人、董事长尹正龙逝世。 公告称，"接公司控股股东、实际控制人、董事长尹正龙先生家属的通知，尹正龙先生已于2025年8月26日下午永远离开了我们，享年60岁。" 据公告，作为公司创始人，自公司成立以来，尹正龙一直担任公司董事长、总经理等职务。尹正龙持有公司股份63057454股，占公司股份总额的 26.90%，为公司控股股东、实际控制人。尹正龙所持的公司股份将按相关法律法规办理相关手续，公司将根据后续事项进展情况及时履行信息披露义 务。 同时，山河药辅表示，尹正龙的逝世不会导致公司董事会成员人数低于法定人数，不会影响公司董事会的正常运作。公司经营管理团队正常履职，各项经 营业务活动不会受到影响。公司董事长职位出现空缺，根据有关法律法规和《公司章程》的规定，公司将尽快完成董事补选、选举董事长等工作。经全体 董事推举，现由公司董事、总经理宋道才暂行行使公司董事长和法定代表人职责，直至公司董事会选举出新的董事长之日止。 值得注意的是，8月18日下午三点钟，山河药辅召开了股东大会，会议主持人正是尹正龙。 公司董事长 ...